Article Text

Download PDFPDF
Hepatitis A and B vaccine uptake and immunisation among men who have sex with men seeking PrEP: a substudy of the ANRS IPERGAY trial
  1. Paul Le Turnier1,2,3,
  2. Isabelle Charreau4,
  3. Audrey Gabassi5,6,
  4. Diane Carette4,
  5. Laurent Cotte7,
  6. Gilles Pialoux8,
  7. Cécile Tremblay9,
  8. Bruno Spire10,
  9. Marie-Laure Chaix5,6,
  10. Laurence Meyer4,11,
  11. Catherine Capitant4,
  12. Constance Delaugerre5,6,
  13. François Raffi1,2,
  14. Jean-Michel Molina6,12
  15. for the ANRS IPERGAY study group
    1. 1 Maladies Infectieuses, Centre Hospitalier Universitaire de Nantes, Nantes, France
    2. 2 CIC-EC 1413, INSERM, Nantes, France
    3. 3 Maladies Infectieuses, Centre Hospitalier de Cayenne, Cayenne, French Guiana
    4. 4 INSERM SC10 US19, Villejuif, France
    5. 5 Laboratoire de Virologie, APHP, Hôpital Saint-Louis, Paris, France
    6. 6 INSERM U944, Institut de Recherche Saint-Louis, Université de Paris, Paris, France
    7. 7 Maladies Infectieuses, Hospices Civils de Lyon, Hôpital de la Croix-Rousse, Lyon, France
    8. 8 Maladies Infectieuses, Hôpital Tenon, Assistance Publique Hôpitaux de Paris, Paris, France
    9. 9 Centre de Recherche, Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada
    10. 10 INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, Aix Marseille Université, Marseille, France
    11. 11 UNiversité Paris-Sud, Université Pris-Saclay, Paris, France
    12. 12 Maladies Infectieuses, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Paris, France
    1. Correspondence to Dr Paul Le Turnier, Centre Hospitalier Universitaire de Nantes, Nantes 44000, France; paul.leturnier{at}


    Vaccination against hepatitis A virus (HAV) and hepatitis B virus (HBV) is recommended in men who have sex with men (MSM). We assessed HAV and HBV vaccine uptake in the non-immune participants and their immunisation during follow-up of the ANRS IPERGAY (Intervention Préventive de l'Exposition aux Risques avec et pour les Gays) pre-exposure prophylaxis (PrEP) trial.

    During the ANRS IPERGAY trial among MSM (NCT 01473472), vaccination against HAV and HBV was offered free of charge to all non-immune participants at baseline. We assessed anti-HAV IgGs and anti-hepatitis B surface (HBs) antibodies (Abs) at baseline, 1–3 months after each vaccine dose and on the last follow-up visit. Vaccination uptake and immunisation were analysed in non-immune participants with at least 6 months of follow-up after the 1st vaccine dose.

    A total of 427 MSM with a median age of 34.8 years were analysed. Median follow-up was 2.2 years (Q1–Q3, 1.6–2.9). Absence of anti-HAV IgG at baseline (50.4%, 215/427) was associated with younger age (p=0.0001). Among HAV non-immune participants, 96.1% (197/205) received one or more vaccine doses and 91.0% (172/189) received two vaccine doses. Among HBV non-immune participants, 97.6 % (81/83) received one or more vaccine doses and 78.4% (58/74) received three doses. On the last-visit sample, anti-HAV IgG and anti-HBs Abs were respectively detected in 94.8% (95% CI 90.0% to 97.7%) and 79.6% (95% CI 66.5% to 89.4%) of participants with complete vaccination and in 80.0% (95% CI 51.9% to 95.7%) and 40.0% (95% CI 16.3% to 67.7%) of participants with incomplete vaccination.

    Vaccine acceptability against HAV and HBV infections was very high in MSM starting PrEP. Immunisation was high in participants with a full vaccination scheme. Physicians must consider PrEP visits as major opportunities to propose and complete HAV and HBV vaccination in at-risk non-immune subjects.

    • Pre-Exposure Prophylaxis

    Statistics from

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


    • Handling editor Tristan J Barber

    • FR and J-MM contributed equally.

    • Collaborators Site Investigators:- Paris St-Louis: C Pintado, B Loze, C Delaugerre, P Charbonneau, C Gatey, D Ponscarme, P Penot, L Niedbalski, R Veron, J Delgado, E Dalle, S Parlier, I Madelaine, J Fonsart, M Danet, N Mahjoub, N Mezreb, K Moudachirou, S Morel, G Conort, F Lorho, M Meunier, W Rozenbaum, JM Molina- Paris Tenon: J Chas, C Monfort, J Foucoin, B Boissavy, S Cousseau, S Huon, M Danet, A Djessima, V Berrebi, A Adda, S le Nagat, L Zarka, J Berdougo, G Pialoux- Lyon: C Chidiac, N Mzoughi, F Clement, A Decouty, C Chapolard, M Godinot, C Adouard-groslafeige, J Koffi, A Pansu, A Becker, S Pailhes, F Bonnet, F Jeanblanc, C Brochier, X Teruin, S Rouby, L Gilly, L Cotte- Montréal: C Beauvais, P Arlotto, C Fortin, A Talbot, A Chamberland, A McKenzie, M Blanchette, R Rousseau, K Montheuth, D Thompson, M Morin, M Wainberg, C Tremblay- Nice: C Etienne, F Tolonin, S Breaud, V Péchenot, S Bagge, T Cepitelli, PM Roger, E Rosenthal, E Cua- Tourcoing: A Cheret, P Cornavin, S Vandamme, J Lambec, N Dumon, O Leclanche, T Huleux, R Biekre, O Robineau, H Melliez, H Bazus, A Pasquet- Nantes: C Bernaud, M Besnier, B Bonnet, N Hall, M Cavellec, H Hue, L Larmet, M Colas, R Choquet, F Raffi Members of the Scientific Committee: Jean-Michel Molina (Chair), Mark Wainberg, Benoit Trottier, Cécile Tremblay, JeanGuy Baril, Gilles Pialoux, Laurent Cotte, Antoine Chéret, Armelle Pasquet, Eric Cua, Michel Besnier, Willy Rozenbaum, Christian Chidiac, Constance Delaugerre, Nathalie Bajos, Julie Timsit, Gilles Peytavin, Julien Fonsart, Isabelle Durand-Zaleski, Laurence Meyer, Jean-Pierre Aboulker, Bruno Spire, Marie Suzan-Monti, Gabriel Girard, Daniela Rojas Castro, Marie Préau, Michel Morin, David Thompson, Catherine Capitant, Lucie Marchand, Véronique Doré, Marie-Christine Simon, Isabelle Charreau, Joanne Otis, France Lert, Alpha Diallo, Séverine Gibowski, and Cecile Rabian. Members of the Independent data and safety monitoring board: Drs. Dominique Costagliola (Chair), Yazdan Yazdanpanah, Vinhh-Kim Nguyen, AnneMarie Taburet, and Corinne Taéron). AIDES community advocacy group and community peer counselors: JM Le Gall, S Morel, V Pechenot, S Bagge, A Djessima Taba, M Danet, K Moudachirou, B Dos Santos, J Lambec, S Rouby, X Teruin, N Dumon, V Coquelin, P Brunet, L Gilly, T Cepitelli, R Porion, D Rojas Castro, B Spire. INSERM SC10-US19 Clinical trial Unit: L Meyer, C Capitant, I Charreau, E Netzer, N Leturque, J Binesse, V Foubert, M Saouzanet, F Euphrasie, B Guillon, Y Saïdi, JP Aboulker. INSERM UMR 912 SESSTIM: B Spire, M Suzan, G Cattin, B Demoulin, L Sagaon-Teyssier, N Lorente.

    • Contributors FR and J-MM equally contributed to this worK.

    • Funding The IPERGAY trial was supported by ANRS, the Canadian HIV Trials Network, the Fonds de Dotation Pierre Bergé pour la Prévention, the Bill and Melinda Gates Foundation and Gilead Sciences. PLT benefited from a financial support by ANRS.

    • Disclaimer This study was presented in part as a poster at the Conference on Retroviruses and Opportunistic Infections on 8–11 March 2020 in Boston.

    • Competing interests J-MM reports grants from Gilead and participated to advisory board for Gilead, Merck and ViiV for studies unrelated to this current work. GP reports grants from Gilead and Bristol Myers Squibb and personal fees (board membership) from Gilead, Bristol Myers Squibb, Boehrringer Ingelheim, Nephrotek, ViiV Healthcare, Abbvie and MSD for studies unrelated to this current work. FR reports personal fees from Gilead, Janssen, MSD, Theratechnologies and ViiV Healthcare for studies unrelated to this current work. All other authors report no potential conflicts and have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

    • Provenance and peer review Not commissioned; internally peer reviewed.